Psychopharmacology and Psychiatry Updates

In this episode, we explore new international guidelines for clozapine monitoring following the FDA's REMS rescission. Should patients on stable clozapine continue lifelong monthly blood draws, or can we safely reduce monitoring after two years? Dr. Seeber discusses how these evidence-based recommendations balance patient burden with safety.
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 79
New Guidelines for Clozapine ANC Monitoring

In this episode, we explore how pregnancy reshapes the pharmacokinetics of psychiatric medications — and what that means for your patients. Can stopping a mood stabilizer actually put a pregnancy at greater risk than continuing it? Dr. Amanda Koire breaks down the evidence.
Faculty: Amanda Koire, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 0.5 CME: Prescribing in Pregnancy: What Every Clinician Should Know
Pregnancy's Impact on Medication Efficacy and Dosing Considerations

In this episode, we explore bright light therapy (BLT) as a powerful adjunctive treatment for bipolar depression — examining the neuroscience behind it, how to implement it clinically, and why it may work faster than medication alone. Could something as simple as light reshape how we treat mood disorders?
Faculty: Kristin Raj, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 80
Bright Light Therapy for Bipolar Depression: ISBD Clinical Recommendations

In this episode, we explore three often-overlooked side effects of lithium — sexual dysfunction, hair loss, and skin changes like acne and psoriasis — and discuss practical, evidence-based strategies for managing each one without abandoning a medication that works.
Faculty: David Osser, M.D.
Host: Richard Seeber, M.D.
Learn more about our memberships here
Earn 1.5 CME: Lithium: How to Manage Dosage and Side Effects
Approaching Sexual Dysfunction, Hair Loss, and Rashes With Lithium

In this episode, we explore KarXT, a newly FDA-approved antipsychotic with a groundbreaking cholinergic mechanism, through the lens of a single powerful metric: the Number Needed to Treat. Could an NNT of 5 change how you approach treatment-resistant schizophrenia?
Faculty: Oliver Freudenreich, M.D.
Host: Richard Seeber, M.D.
Learn more about our membership here
Earn 0.75 CMEs: Quick Take Vol. 80
How Effective Is KarXT (Xanomeline-Trospium) for Schizophrenia? NNT and NNH Explained